metaPreg - Vedolizumab during pregnancy

Vedolizumab

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	2.62 [0.52, 13.35]	-	1 study	6	64	not evaluable	ROB	-
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preterm (< 37 weeks)	2.33 [0.95, 5.70]	-	1 study	22	64	not evaluable	ROB	-
Small for gestational age (weight)	1.72 [0.28, 10.55]	-	1 study	5	64	not evaluable	ROB	-
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Neonatal infections	0.37 [0.09, 1.48]	-	1 study	10	64	not evaluable	ROB	-
Hide endpoints reported in only one study ...